Trade Invivyd Inc. - IVVD CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022235 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.000012 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022235 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.000012 %
  ($0.00)

Key Stats

• Prev. Close: 0.83
• Open: 0.83
• 1-Year Change: -27.19%
• Day's Range: 0.79 - 0.83

Trade Invivyd Inc. - IVVD

About Adagio Therapeutics Inc

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).